Welcome to our dedicated page for Tg Therapeutics SEC filings (Ticker: TGTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TG Therapeutics' SEC filings document a commercial-stage biotechnology issuer whose common stock trades on the Nasdaq Capital Market under TGTX. The filings cover operating results and financial condition, BRIUMVI product revenue and revenue guidance, license, royalty and other commercialization revenue, and research and development spending tied to its B-cell disease pipeline.
Material-event filings also record capital-structure actions such as senior secured credit financing, repayment of prior term loans, and related borrowing terms. Proxy materials disclose board elections, executive compensation, equity awards, shareholder voting matters, and governance practices for the public company.
TG Therapeutics reported positive Phase 1 results for a high‑concentration, low‑volume subcutaneous formulation of BRIUMVI (ublituximab-xiiy) in adults with relapsing multiple sclerosis. The subcutaneous version was well tolerated and showed sustained drug exposure, supporting a quarterly dosing regimen.
These data underpin an ongoing, fully enrolled Phase 3 trial comparing quarterly and every‑other‑month subcutaneous dosing to the approved intravenous regimen, with topline results expected in late 2026 or early 2027. Management noted that, if ultimately approved, a self‑administered at‑home, quarterly anti‑CD20 therapy could significantly reduce injections versus current options and expand the addressable BRIUMVI market.
TG Therapeutics reported positive topline results from its Phase 3 ENHANCE trial of BRIUMVI in adults with relapsing forms of multiple sclerosis. The study met its primary endpoint, showing bioequivalent drug exposure between the currently approved two-step initiation regimen and a single 600 mg infusion on Day 1.
This consolidated regimen would eliminate the Day 15 infusion while keeping the same total 600 mg dose through Day 15. Safety and tolerability of the single-infusion start were consistent with the established BRIUMVI safety profile. The company is targeting submission of a supplemental biologics license application in the second half of 2026.
TG Therapeutics reported strong growth and continued profitability for the quarter ended March 31, 2026. Total revenue reached $204.9 million, up from $120.9 million a year earlier, driven mainly by BRIUMVI sales of $201.3 million, including $194.8 million in the U.S. and $6.5 million to ex-U.S. partner Neuraxpharm.
Net income rose to $19.8 million from $5.1 million, with diluted earnings per share of $0.12. The company ended the quarter with $572.8 million in cash, cash equivalents and investment securities and estimates these resources, together with projected revenues, will fund operations for more than twelve months.
TG Therapeutics refinanced its prior $250 million term loan with a new $750 million term loan maturing in 2031, recognizing a $9.2 million loss on extinguishment of debt. It also continued its share repurchase activity, holding 6.9 million shares in treasury at a cost of about $200.2 million.
TG Therapeutics reported sharply improved first quarter 2026 results, driven by strong uptake of BRIUMVI for multiple sclerosis. Total revenue reached $204.9 million, up from $120.9 million a year earlier, producing operating income of $34.8 million and net income of $19.8 million.
Product revenue, mainly from BRIUMVI, was $201.3 million, while cash, cash equivalents and investment securities grew to $572.8 million as of March 31, 2026. Despite higher research, selling, general and administrative expenses, profitability and cash balances increased.
Reflecting this momentum, the company raised its full-year 2026 total global revenue target to about $925 million and increased its BRIUMVI U.S. net product revenue guidance to $885–900 million, signaling confidence in ongoing demand and commercial execution.
TG Therapeutics, Inc. is soliciting proxies for its 2026 virtual Annual Meeting, where stockholders will elect six directors, ratify KPMG LLP as auditor, and cast an advisory vote on executive pay.
The company reports 153,093,879 common shares outstanding as of April 14, 2026 and notes directors and executive officers collectively own or can acquire about 8.87% of those shares. Annual bonuses for 2025 paid out at 131% of target, reflecting performance against commercial, clinical, and operational goals.
CEO Michael S. Weiss receives a fixed salary of $875,000 and a fully performance-based equity program tied to total shareholder return versus the Nasdaq Biotechnology Index, including a 2025 grant of 750,000 restricted shares. CFO Sean A. Power’s 2025 base salary is $500,000, with 50% target bonus and multi-year vesting restricted stock. KPMG’s 2025 audit fees totaled about $1.54 million, with additional tax services and minimal other fees, all pre-approved by the Audit Committee, which has determined the firm’s independence.
TG Therapeutics Inc reported a passive Schedule 13G ownership filing by Vanguard Portfolio Management. The filing shows 8,400,210 shares beneficially owned, representing 5.26% of common stock as of 03/31/2026. The filing states these holdings are held on behalf of Vanguard funds and managed accounts.
The Vanguard Group filed Amendment No. 6 to a Schedule 13G/A reporting 0 shares ( 0% ) of TG Therapeutics Inc common stock. The amendment explains an internal realignment on January 12, 2026 that caused certain subsidiaries or business divisions to report disaggregated beneficial ownership in reliance on SEC Release No. 34-39538. The filing states The Vanguard Group no longer is deemed to beneficially own securities reported by those subsidiaries following the realignment. The form is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
TG Therapeutics entered into a major debt amendment that creates a new $750 million 2026 term loan, which was fully drawn on March 18, 2026. Part of the proceeds repaid the company’s existing initial term loans, effectively refinancing its capital structure while keeping Blue Owl Capital Corporation as administrative agent.
The loan matures on March 18, 2031 and carries a variable interest rate based on either a base rate or Term SOFR, plus a margin tied to the company’s total net leverage ratio. Margins start at 4.75% for SOFR and 3.75% for base rate borrowings and can step down by 0.25% if leverage improves. Beginning in the quarter ending March 31, 2030, the agreement requires quarterly principal payments of $37.5 million, with the remaining balance due at maturity, though these installments may be deferred to maturity if a leverage threshold is met.
The 2026 term loan is secured by liens on substantially all assets of TG Therapeutics and certain subsidiaries and includes customary covenants and default provisions for this type of financing, giving lenders rights to accelerate repayment if an event of default occurs.
TG Therapeutics files its annual report describing a focused strategy on B‑cell–mediated diseases, led by its approved multiple sclerosis therapy BRIUMVI (ublituximab‑xiiy). BRIUMVI is marketed in the U.S. and, through a commercialization deal with Neuraxpharm, is being rolled out across parts of Europe and other ex‑U.S. territories.
The company highlights long‑term Phase 3 data showing very low annualized relapse rates and stable safety for BRIUMVI, and is running late‑stage programs for a subcutaneous formulation and simplified IV dosing. It is also advancing azer‑cel, an allogeneic CD19 CAR‑T for progressive multiple sclerosis, under an exclusive license from Precision.
TG Therapeutics reports robust intellectual property, including U.S. patent protection on BRIUMVI compositions potentially extending to 2042 and 12 years of U.S. biologic exclusivity from its 2022 approval. The report also notes completion of a $100 million share repurchase program and outlines extensive regulatory, commercialization, financing, manufacturing, and compliance risks inherent to its business.
TG Therapeutics reported strong growth for the fourth quarter and full year 2025, led by BRIUMVI. Q4 2025 total revenue was $192.6 million, including BRIUMVI U.S. net revenue of $182.7 million. Full-year 2025 total revenue reached $616.3 million, with BRIUMVI U.S. net revenue of $594.1 million.
Total 2025 revenue rose sharply from $329.0 million in 2024, and net income increased to $447.2 million from $23.4 million. The company issued 2026 guidance targeting approximately $875–900 million in total global revenue, Q1 2026 BRIUMVI U.S. net product revenue of $185–190 million, and about $350 million in operating expenses plus $100 million in subcutaneous BRIUMVI manufacturing and start-up costs.